Does the media prefer IMVT or ROIV?

In the previous week, Roivant Sciences had 7 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Roivant Sciences and 7 mentions for Immunovant. Roivant Sciences' average media sentiment score of 1.34 beat Immunovant's score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Immunovant N/A -65.66% -59.88%

Does the media refer more to MRNA or IMVT?

In the previous week, Moderna had 7 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Moderna and 7 mentions for Immunovant. Immunovant's average media sentiment score of 0.71 beat Moderna's score of 0.42 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or INSM more profitable?

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Insmed -144.44% -130.11% -51.57%

Does the media prefer IMVT or INSM?

In the previous week, Insmed had 15 more articles in the media than Immunovant. MarketBeat recorded 22 mentions for Insmed and 7 mentions for Immunovant. Insmed's average media sentiment score of 1.07 beat Immunovant's score of 0.71 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 12 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is BNTX or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Immunovant N/A -65.66% -59.88%

Does the media favor BNTX or IMVT?

In the previous week, BioNTech had 2 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for BioNTech and 7 mentions for Immunovant. BioNTech's average media sentiment score of 0.97 beat Immunovant's score of 0.71 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$39.41 +0.04 (+0.10%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$38.66 -0.75 (-1.90%)

As of 07/24/2026 07:34 PM Eastern

Compare

IMVT vs. SLNO, ROIV, MRNA, INSM, and BNTX

Should you buy Immunovant stock or one of its competitors? MarketBeat compares Immunovant with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunovant include Soleno Therapeutics (SLNO), Roivant Sciences (ROIV), Moderna (MRNA), Insmed (INSM), and BioNTech (BNTX). These companies are all part of the "medical" sector.

How does Immunovant compare to Soleno Therapeutics?

Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Immunovant had 7 more articles in the media than Soleno Therapeutics. MarketBeat recorded 7 mentions for Immunovant and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 beat Immunovant's score of 0.71 indicating that Soleno Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunovant	Positive
Soleno Therapeutics	Positive

Immunovant has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, indicating that its share price is 322% less volatile than the broader market.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunovant currently has a consensus price target of $39.70, suggesting a potential upside of 0.74%. Soleno Therapeutics has a consensus price target of $76.67, suggesting a potential upside of 44.63%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Soleno Therapeutics has a net margin of 33.70% compared to Immunovant's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Soleno Therapeutics	33.70%	22.85%	18.25%

Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

Summary

Soleno Therapeutics beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Immunovant (NASDAQ:IMVT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Roivant Sciences had 7 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Roivant Sciences and 7 mentions for Immunovant. Roivant Sciences' average media sentiment score of 1.34 beat Immunovant's score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Immunovant currently has a consensus target price of $39.70, suggesting a potential upside of 0.74%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential downside of 4.05%. Given Immunovant's higher probable upside, research analysts clearly believe Immunovant is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Roivant Sciences	$8.26M	3,048.63	-$299.77M	-$0.60	N/A

Summary

Roivant Sciences beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Immunovant compare to Moderna?

Moderna (NASDAQ:MRNA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Immunovant has lower revenue, but higher earnings than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	9.73	-$2.82B	-$8.15	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Moderna currently has a consensus target price of $40.00, indicating a potential downside of 26.02%. Immunovant has a consensus target price of $39.70, indicating a potential upside of 0.74%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Moderna had 7 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Moderna and 7 mentions for Immunovant. Immunovant's average media sentiment score of 0.71 beat Moderna's score of 0.42 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Immunovant	N/A	-65.66%	-59.88%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Moderna beats Immunovant on 8 of the 15 factors compared between the two stocks.

How does Immunovant compare to Insmed?

Immunovant (NASDAQ:IMVT) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Insmed had 15 more articles in the media than Immunovant. MarketBeat recorded 22 mentions for Insmed and 7 mentions for Immunovant. Insmed's average media sentiment score of 1.07 beat Immunovant's score of 0.71 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	12 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Immunovant has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Insmed	$606.42M	38.22	-$1.28B	-$5.75	N/A

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Insmed	-144.44%	-130.11%	-51.57%

Immunovant currently has a consensus target price of $39.70, suggesting a potential upside of 0.74%. Insmed has a consensus target price of $209.13, suggesting a potential upside of 95.60%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Insmed beats Immunovant on 10 of the 16 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Immunovant has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.05	-$1.29B	-$5.88	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, BioNTech had 2 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for BioNTech and 7 mentions for Immunovant. BioNTech's average media sentiment score of 0.97 beat Immunovant's score of 0.71 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 44.55%. Immunovant has a consensus target price of $39.70, indicating a potential upside of 0.74%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Immunovant	N/A	-65.66%	-59.88%

Summary

BioNTech beats Immunovant on 11 of the 16 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.08B	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-14.18	21.11	27.00	23.71
Price / Sales	N/A	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	9.41	7.88	10.28	6.07
Net Income	-$505.61M	$23.81M	$3.60B	$331.84M
7 Day Performance	-2.11%	-3.79%	-1.25%	-1.53%
1 Month Performance	3.06%	-2.59%	-0.35%	-2.46%
1 Year Performance	132.51%	32.85%	18.41%	13.66%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	1.5451 of 5 stars	$39.41 +0.1%	$39.70 +0.7%	+115.1%	$8.08B	N/A	N/A	120
SLNO Soleno Therapeutics	N/A	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
ROIV Roivant Sciences	1.644 of 5 stars	$34.05 -1.3%	$33.59 -1.3%	+207.6%	$24.82B	$8.26M	N/A	860	News Coverage Positive News
MRNA Moderna	1.5765 of 5 stars	$59.49 -3.8%	$38.80 -34.8%	+59.0%	$24.53B	$1.94B	N/A	4,700	Upcoming Earnings Analyst Forecast
INSM Insmed	3.8926 of 5 stars	$107.02 -1.2%	$209.13 +95.4%	+3.3%	$23.48B	$606.42M	N/A	1,664	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. SLNO, ROIV, MRNA, INSM, and BNTX

How does Immunovant compare to Soleno Therapeutics?

Summary

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to Moderna?

Summary

How does Immunovant compare to Insmed?

Summary

How does Immunovant compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. SLNO, ROIV, MRNA, INSM, and BNTX

How does Immunovant compare to Soleno Therapeutics?

Does the media favor IMVT or SLNO?

Which has more risk and volatility, IMVT or SLNO?

Do insiders & institutionals believe in IMVT or SLNO?

Do analysts rate IMVT or SLNO?

Is IMVT or SLNO more profitable?

Which has stronger valuation and earnings, IMVT or SLNO?

Summary

How does Immunovant compare to Roivant Sciences?

Does the media prefer IMVT or ROIV?

Do insiders and institutionals hold more shares of IMVT or ROIV?

Is IMVT or ROIV more profitable?

Which has more risk and volatility, IMVT or ROIV?

Do analysts prefer IMVT or ROIV?

Which has stronger earnings and valuation, IMVT or ROIV?

Summary

How does Immunovant compare to Moderna?

Which has stronger valuation & earnings, MRNA or IMVT?

Do analysts recommend MRNA or IMVT?

Does the media refer more to MRNA or IMVT?

Which has more volatility and risk, MRNA or IMVT?

Is MRNA or IMVT more profitable?

Do institutionals and insiders have more ownership in MRNA or IMVT?

Summary

How does Immunovant compare to Insmed?

Do insiders & institutionals hold more shares of IMVT or INSM?

Which has more volatility & risk, IMVT or INSM?

Does the media prefer IMVT or INSM?

Which has stronger earnings & valuation, IMVT or INSM?

Is IMVT or INSM more profitable?

Do analysts recommend IMVT or INSM?

Summary

How does Immunovant compare to BioNTech?

Which has higher earnings and valuation, BNTX or IMVT?

Which has more volatility & risk, BNTX or IMVT?

Do insiders and institutionals have more ownership in BNTX or IMVT?

Does the media favor BNTX or IMVT?

Do analysts rate BNTX or IMVT?

Is BNTX or IMVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools